Biosyent (CVE:RX) posted its quarterly earnings results on Wednesday. The company reported C$0.10 earnings per share for the quarter, meeting the consensus estimate of C$0.10, reports. The firm had revenue of C$5.90 million for the quarter. Biosyent had a return on equity of 25.90% and a net margin of 23.96%.

Biosyent (CVE RX) traded down C$0.19 during trading hours on Friday, reaching C$9.51. The company had a trading volume of 100 shares, compared to its average volume of 11,407. The firm has a market capitalization of $139.88, a price-to-earnings ratio of 28.82 and a beta of 1.11. Biosyent has a 52-week low of C$7.30 and a 52-week high of C$11.00.

TRADEMARK VIOLATION NOTICE: This story was first reported by Watch List News and is the property of of Watch List News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. & international trademark and copyright laws. The original version of this story can be viewed at

About Biosyent

BioSyent Inc is a specialty pharmaceutical company. The Company, through its subsidiary, BioSyent Pharma Inc, acquires or in-licenses and develops pharmaceutical products for sale in Canada and certain international markets. It has four business units: the Community and Women’s Health Unit, which commercializes pharmaceutical products focused on improving family and women’s health; the Hospital Business Unit, which sells pharmaceutical products to hospitals and hospital specialists; the International Pharmaceutical Unit, and the Legacy Business.

Earnings History for Biosyent (CVE:RX)

Receive News & Ratings for Biosyent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biosyent and related companies with's FREE daily email newsletter.